Minimal Residual Disease (MRD) Detection of NSCLC with Microfluidic-Capture Microdissection (MCM) System
The SACA system, which utilizes a variety of technology including a dynamic Live- cell Staining Microdialysis Chip and Patient-Derive Explants Platform used for profiling, allows for more efficient response assessment and selection for cancer immunotherapy. We developed a Microfluidic-capture Microdissection (MCM) system for single cell isolation based on nondestructive sampling, providing highly customized & quality total solutions to procure subpopulations of live tissue cells or PMBC in blood.
Targeted indication
Monitoring immune responses in the tumor microenvironment
Status
Prototype platform of Microfluidic-capture Microdissection (MCM) for validation of the possibility of Minimal residual disease (MRD) in NSCLC
Key features
- Realtime monitoring of tumor associated macrophage
- Microdissection the desired cell in a targeted group
- Keep all targeted tumor cells are viability for RNAseq
Market
MODE OF ACTION
EXPERIMENTAL RESULTS
Proof of IEC61010-1 &61326-1
In clinical performance study with China Medical University Hsinchu Hospital
Plan to start the clinical trials (pivotal studies) at 2024 Q1
On the way of building up the SOP of MRD processing that ruled by FDA draft guidance to assist with the use of minimal residual disease as a biomarker of tumor burden quantification
INTELLECTUAL PROPERTY
SELECTED PUBLICATIONS
17+ Journal papers
BUSINESS OPPORTUNITY
✓ IO combination therapies dynamic monitoring
✓ Spatial Heterogeneity
✓ Intratumoral heterogeneity
✓ Co-development with strategy partners is focused on improving the ORR by dynamic monitoring immune responses in the tumor microenvironment
CONTACT
service@biip-dcc.org